<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Primary care diagnosis and management of adults with depression.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Primary care diagnosis and management of adults with depression. Southfield (MI): Michigan Quality Improvement Consortium; 2014 Jan. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Primary care diagnosis and management of adults with depression. Southfield (MI): Michigan Quality Improvement Consortium; 2012 Jan. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="HCPCS: Alcohol and/or drug assessment ; Alcohol and/or drug screening ; Mental health services, not otherwise specified "/><FieldValue Value="ICD9CM: Bipolar disorder, unspecified  (296.80); Major depressive affective disorder, recurrent episode, unspecified  (296.30); Major depressive affective disorder, single episode, unspecified  (296.20); Suicidal ideation  (V62.84); Unspecified psychosis  (298.9)"/><FieldValue Value="MSH: Antidepressive Agents ; Bipolar Disorder ; Depression ; Depression, Postpartum ; Depressive Disorder ; Depressive Disorder, Major ; Diagnostic and Statistical Manual of Mental Disorders ; Medication Therapy Management ; Mental Health Services ; Primary Health Care ; Psychotic Disorders ; Referral and Consultation ; Risk Assessment ; Suicidal Ideation ; Suicide "/><FieldValue Value="MTH: Antidepressive Agents ; Bipolar Disorder ; Depression screen ; Depressive Disorder ; Drug abuse screening test ; Edinburgh postnatal depression scale (assessment scale) ; Feeling suicidal (finding) ; MAJOR DEPRESSIVE DISORDER ; Mental Depression ; Patient Health Questionnaire ; PHQ-9 quick depression assessment panel:-:Pt:^Patient:-:Reported.PHQ-9 ; Primary Health Care ; Psychotic Disorders ; Recurrence ; Risk Assessment ; Suicide "/><FieldValue Value="SNOMEDCT_US: Antidepressant  (36236003); Antidepressant  (372720008); Assessment of substance use  (428211000124100); Bipolar disorder  (13746004); Depression management program  (401174001); Depression screening  (171207006); Depressive disorder  (21061000119107); Depressive disorder  (35489007); Drug abuse screening test  (273426006); Edinburgh postnatal depression scale  (273441006); Feeling suicidal  (225457007); Feeling suicidal  (6471006); Major depressive disorder  (370143000); Mental health service  (708168004); Patient health questionnaire-nine item  (473012008); Postpartum depression  (58703003); Psychotic disorder  (69322001); Recurrence  (246455001); Recurrent major depressive episodes  (268621008); Recurrent major depressive episodes  (66344007); Referral to mental health team  (390866009); Risk assessment  (225338004); Single major depressive episode  (268620009); Single major depressive episode  (36923009); Suicide  (44301001); Suicide risk assessment  (225337009)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Major depressive disorder&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Psychiatry" /><FieldValue Value="Psychology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Plans" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To achieve significant, measurable improvements in the diagnosis and management of depression through the development and implementation of common evidence-based clinical practice guidelines &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To design concise guidelines that are focused on key management components of depression to improve outcomes &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adults 18 years or older with high risk for major depressive disorder, including conditions such as prenatal and postpartum; chronic medication use, disabling illness and/or pain; anxiety &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Individuals diagnosed with significant mood symptoms, particularly those meeting criteria for major depression &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Screening&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assessment for major depression using:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Patient Health Questionnaire (PHQ)-2 and PHQ-9 &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Edinburgh Postnatal Depression Scale (EPDS) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of drug and alcohol use &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of symptoms suggesting bipolar disorder or psychosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of suicide risk &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Antidepressant medication &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral to a behavioral health specialist &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Frequent monitoring of medication with adjustment as indicated &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Continuation of medication for 9 to 12 months after acute symptoms resolve &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Michigan Quality Improvement Consortium (MQIC) health care analyst conducts a search of current literature in support of the guideline topic. Computer database searches are used to identify published studies, existing protocols, and/or national guidelines on the selected topic developed by organizations such as the American Diabetes Association, American Heart Association, American Academy of Pediatrics, etc. If available, clinical practice guidelines from participating MQIC health plans and Michigan health systems are also used to develop a framework for the new guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For the current update of the guideline PubMed, U.S. Preventive Services Task Force (USPSTF), Institute for Clinical Systems Improvement (ICSI), and National Institute of Mental Health databases were searched from January 2012 to December 2013. Specific search terms included depression symptoms, depression screening postpartum, antidepressant monitoring, Edinburgh Postnatal Depression Scale.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational studies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Using information obtained from literature searches and available health plan guidelines on the designated topic, the Michigan Quality Improvement Consortium (MQIC) health care analyst prepares a draft guideline to be reviewed by the medical directors' committee at one of their scheduled meetings. Priority is given to recommendations with [A] and [B] levels of evidence (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The initial draft guideline is reviewed, evaluated, and revised by the committee, resulting in draft two of the guideline. Additionally, the Michigan Academy of Family Physicians participates in guideline development at the onset of the process and throughout the guideline development procedure. The MQIC guideline feedback form and draft two of the guideline are distributed to the medical directors, as well as the MQIC measurement and implementation group members, for review and comments. Feedback from members is collected by the MQIC health care analyst and prepared for review by the medical directors' committee at their next scheduled meeting. The review, evaluation, and revision process with several iterations of the guideline may be repeated over several meetings before consensus is reached on a final draft guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;When consensus is reached on the final draft guideline, the medical directors approve the guideline for external distribution to practitioners with review and comments requested via the Michigan Quality Improvement Consortium (MQIC) health plans (health care analyst distributes final draft to medical directors' committee, measurement and implementation groups to solicit feedback).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst also forwards the approved guideline draft to appropriate state medical specialty societies and physicians with expertise in the related field for their input. After all feedback is received from external reviews, it is presented for discussion at the next scheduled committee meeting. Based on feedback, subsequent guideline review, evaluation, and revision may be required prior to final guideline approval.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC Medical Directors approved this updated guideline in January 2014.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The level of evidence grades (&lt;strong&gt;A&amp;ndash;D&lt;/strong&gt;) are provided for the most significant recommendations and are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Adults 18 Years or Older with High Risk for Major Depressive Disorder (Including Conditions Such as Prenatal and Postpartum; Chronic Medication Use, Disabling Illness and/or Pain; Anxiety)&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Detection and Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assess for major depression using a validated screening tool (e.g., Patient Health Questionnaire [PHQ]-2) and diagnostic tool (e.g., PHQ-9), &lt;strong&gt;or&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess if criteria for major depression are met using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). &lt;strong&gt;[A]&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;Must have a total of five symptoms for at least two weeks. One of the symptoms must be depressed mood or loss of interest. Relevant symptoms include:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Little interest or pleasure in doing things &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Feeling down, depressed, or hopeless &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Insomnia/hypersomnia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Feeling tired or having little energy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Poor appetite or overeating &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Feeling bad about one's self (failure, let yourself or family down) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Trouble concentrating &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Moving/speaking so slowly that others could have noticed, or fidgety/restless &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Thoughts of being better off dead, or of hurting one's self &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess for drug and alcohol use. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Assess by 3 to 8 weeks postpartum using the Edinburgh Postnatal Depression Scale&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assess whether patients have symptoms suggesting bipolar disorder &lt;strong&gt;[C]&lt;/strong&gt;, or psychosis. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Frequency&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;At each evaluation where the patient's high-risk status, symptoms, or signs raise suspicion of current or uncontrolled depression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;At the first prenatal care visit; on post-partum visits (within 3 to 8 weeks of discharge) and if symptoms or signs raise suspicion &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Individuals Diagnosed with Significant Mood Symptoms, Particularly Those Meeting Criteria for Major Depression&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Screening for Suicide Risk&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assess risk of suicide by direct questioning about suicidal ideation and, if present, suicidal planning, potential means, and personal/family history of suicidal attempts. &lt;strong&gt;[D]&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;If patient at risk for suicide, refer to emergency department or crisis intervention center&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Frequency&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At each encounter addressing depression until patient is treated to remission and has not expressed suicidal thinking in previous visits&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Patients Who Are Prescribed Antidepressant Medication&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Initiate antidepressant medication following manufacturer's recommended doses. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider referral to Behavioral Health Specialist when &lt;strong&gt;[D]&lt;/strong&gt;:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Additional counseling as desired &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Primary physician not comfortable managing patient's depression &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Diagnosis is uncertain or complicated by other psychiatric factors (e.g., bipolar disorder, psychosis, substance abuse) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Complex social situation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Management is complex, response to medication at therapeutic dosage is not optimal, or considering prescribing multiple agents &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psychotherapy and/or hospitalization required &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitor medication frequently (e.g., every two weeks) and adjust to a therapeutic level as assessed by clinical data not to exceed the highest recommended dose. &lt;strong&gt;[D]&lt;/strong&gt; Medication should not be abruptly discontinued. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If no response after approximately 2 to 3 weeks on therapeutic dosage, increase dosage as tolerated and begin new observation period. If no response after approximately 2 to 3 weeks on maximal dosage, then switch antidepressant. If partial response on maximal dosage, then switch antidepressant or augment with additional agent. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with recurrent major depression usually require lifelong treatment. Continue medication for at least 9 to 12 months after acute symptoms resolve. &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Frequency&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Schedule sufficient follow-up visits to assess response to treatment and titrate dose (typically every two weeks, monthly at a minimum). &lt;strong&gt;[D]&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational studies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence is provided for the most significant recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline is based on several sources, including the Adult Depression in Primary Care health care guideline. Institute for Clinical Systems Improvement, October 2013 (&lt;a href=&quot;http://www.icsi.org&quot; title=&quot;ICSI web site&quot;&gt;www.icsi.org&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Through a collaborative approach to developing and implementing common clinical practice guidelines and performance measures for diagnosis and management of depression, Michigan health plans will achieve consistent delivery of evidence-based services and better health outcomes. This approach also will augment the practice environment for physicians by reducing the administrative burdens imposed by compliance with diverse health plan guidelines and associated requirements.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Individual patient considerations and advances in medical science may supersede or modify these recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Approved Michigan Quality Improvement Consortium (MQIC) guidelines are disseminated through email, U.S. mail, and websites.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst prepares approved guidelines for distribution. Portable Document Format (PDF) versions of the guidelines are used for distribution.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst distributes approved guidelines to the MQIC membership via email.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to website vendor to post approved guidelines to the &lt;a href=&quot;http://www.mqic.org&quot; title=&quot;MQIC Web site&quot;&gt;MQIC website&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst completes an annual statewide postcard mailing to physicians in all areas of medicine including primary care and specialties. The postcard provides the complete list of MQIC guidelines and includes which have been recently revised, which are coming up for revision, and any new published guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The statewide mailing list is derived from the Blue Cross Blue Shield of Michigan (BCBSM) provider database. Approximately 95% of the state's MDs and 96% of the state's DOs are included in the database.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to the National Guideline Clearinghouse (NGC) to post approved guidelines to the &lt;a href=&quot;http://www.guideline.gov&quot; title=&quot;NGC Web site&quot; target=&quot;_blank&quot;&gt;NGC website&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Primary care diagnosis and management of adults with depression. Southfield (MI): Michigan Quality Improvement Consortium; 2014 Jan. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is based on several sources, including the Adult Depression in Primary Care health care guideline. Institute for Clinical Systems Improvement, October 2013 (&lt;a href=&quot;http://www.icsi.org&quot; title=&quot;ICSI web site&quot;&gt;www.icsi.org&lt;/a&gt;).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2004 Jan (revised 2014 Jan)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Michigan Quality Improvement Consortium - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium Medical Directors' Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Physician representatives from the 13 participating Michigan Quality Improvement Consortium health plans, Michigan State Medical Society, Michigan Osteopathic Association, Michigan Association of Health Plans, Michigan Department of Community Health, Michigan Peer Review Organization, and the University of Michigan Health System&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Standard disclosure is requested from all individuals participating in the Michigan Quality Improvement Consortium (MQIC) guideline development process, including those parties who are solicited for guideline feedback (e.g., health plans, medical specialty societies). Additionally, members of the MQIC Medical Directors' Committee are asked to disclose all commercial relationships as well.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Primary care diagnosis and management of adults with depression. Southfield (MI): Michigan Quality Improvement Consortium; 2012 Jan. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://mqic.org/pdf/mqic_primary_care_diagnosis_and_management_of_adults_with_depression_cpg.pdf&quot; title=&quot;MQIC Web site&quot;&gt;Michigan Quality Improvement Consortium Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The Edinburgh Postnatal Depression Scale (EPDS). Electronic copies: Available from the &lt;a href=&quot;http://www.mqic.org/physician-tools.htm&quot; title=&quot;Michigan Quality Improvement Consortium (MQIC) Web site&quot;&gt;Michigan Quality Improvement Consortium (MQIC) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient Health Questionnaire (PHQ-9) for Depression. Electronic copies: Available from the &lt;a href=&quot;http://www.mqic.org/physician-tools.htm&quot; title=&quot;Michigan Quality Improvement Consortium (MQIC) Web site&quot;&gt;MQIC Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on December 10, 2004. The information was verified by the guideline developer on January 21, 2005. This summary was updated by ECRI on August 15, 2005, following the U.S. Food and Drug Administration advisory on antidepressant medications. This NGC summary was updated by ECRI on October 12, 2006. The updated information was verified by the guideline developer on November 3, 2006. This summary was updated by ECRI Institute on November 9, 2007, following the U.S. Food and Drug Administration advisory on Antidepressant drugs. This summary was updated by ECRI Institute on April 14, 2008. The updated information was verified by the guideline developer on April 18, 2008. This summary was updated by ECRI Institute on July 28, 2008. The updated information was verified by the guideline developer on July 29, 2008. This summary was updated by ECRI Institute on June 2, 2010. The updated information was verified by the guideline developer on June 28, 2010. This NGC summary was updated by ECRI Institute on May 29, 2012. The updated information was verified by the guideline developer on June 25, 2012. This NGC summary was updated by ECRI Institute on April 15, 2014. The updated information was verified by the guideline developer on April 25, 2014.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which may be reproduced with the citation developed by the Michigan Quality Improvement Consortium.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
